The U.S. Food and Drug Administration approved Sanofi’s Dupixent (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg. With this approval, Dupixent is the first and only medicine specifically indicated to treat EoE in the United States.
Positive Clinical Results Advance Treatments For Multiple Myeloma, Asthma, Alzheimer’s
Alzheimer’s disease, Asthma, AstraZeneca, Biotech/Biopharma, Blood Tests, Clinical Data, Clinical Trials, Hematological Cancers, Lung Disease, Multiple myeloma, Neurodegenerative Disorders, New England Journal of Medicine, R&D, Sanofi, TherapeuticsIn recent months, the biotech and biopharma industries have been struggling with layoffs and dropping stocks. However, some companies are still experiencing success. Sanofi, AstraZeneca, Avillion and Diadem recently announced positive clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
Arkansas sues drugmakers, pharmacy benefit managers over insulin costs
Arkansas, Blockbusters, Cigna, CVS Health, Eli Lilly, Express Scripts Holding, Insulin, Lawsuits, Novo Nordisk, OptumRx, Pharmacy Benefit Managers, Prescription Drug Costs, Retail Pharmacies, Sanofi, Therapeutics, UnitedHealth GroupThe Arkansas attorney general on May 11 accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.
AstraZeneca and Sanofi’s Phase III and Phase IIb clinical trials investigating the efficacy of nirsevimab, measured through the development of secondary infections, are impressing the pharma community with positive prespecified pooled analysis results. The data shows 79.5 percent efficacy in the prevention of lower respiratory tract infections, caused by infection of the respiratory syncytial virus (RSV).
Regeneron Overcomes Loss of COVID Antibody to Post Positive First Quarter
Acquisitions, Biologics License Application (BLA), Blockbusters, Business, COVID-19 Antibodies, FDA, Monoclonal Antibodies, Quarterly results, REGEN-COV (casirivimab and imdevimab), Regeneron Pharmaceuticals, Sales, Sanofi, TherapeuticsDespite the loss of the company’s COVID-19 antibody REGEN-COV earlier in 2022, Regeneron posted a positive first quarter driven primarily by sales of Dupixent and Eylea.
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Approvals, Asthma, EMA, European Commission, Expanded Approval, Marketing Authorization Application (MAA), Monoclonal Antibodies, Pediatric Asthma, Regeneron Pharmaceuticals, Sanofi, Severe Asthma, Severe Pediatric Asthma, TherapeuticsApproval based on Phase 3 data showing Dupixent significantly reduced severe asthma attacks and also improved lung function and health-related quality of life for children Data reinforce well-established safety profile […]
Lexicon, BridgeBio, Esperion, Pfizer, More Celebrate Wins at 71st ACC Meeting
AstraZeneca, BioSpace, Cholesterol, Clinical Data, Clinical Trial Endpoints, Elevated Low-Density Lipoprotein Cholesterol (LDL-C), Heart Attacks, Heart Failure with Reduced Ejection Fraction (HFrEF), Pfizer, Primary Endpoints, R&D, Regeneron Pharmaceuticals, Sanofi, Small-Interfering RNA (siRNA) Class, Strokes, TTR Amyloidosis (ATTR)The 71st annual American College of Cardiology’s Scientific Session saw several wins – and some “mehs” led by some of biopharma’s largest companies, according to BioSpace.
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Blockbusters, Eosinophilic Cells, Eosinophilic Esophagitis, Inflammatory Diseases, Regeneron Pharmaceuticals, Research & Development, Sanofi, Spplemental Biologics License Application (sBLA), TherapeuticsThe U.S. Food and Drug Administration accepted for Priority Review the supplemental Biologics License Application for Dupixent (dupilumab) 300 mg weekly to treat adult and pediatric patients aged 12 years and older with eosinophilic esophagitis (EoE), a chronic and progressive type 2 inflammatory disease that damages the esophagus and impairs the ability to swallow.
Sanofi plans to list the company’s drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.
The high cost of insulin to treat diabetes would be drastically reduced under legislation the U.S. House of Representatives passed on March 31, in a rare example of drug price reform gaining traction in Congress.